No Data
No Data
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
NextCure Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.
Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.
Needham Reiterates Buy on NextCure, Maintains $4 Price Target
Needham analyst Gil Blum reiterates NextCure with a Buy and maintains $4 price target.
Buy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financials
Promising Clinical Trial Results Position NextCure's NC410 as a Potential Game-Changer in Cancer Treatment
NextCure (NXTC.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.61 dollars, previous value of -0.58 dollars, expected value of -0.59 dollars.
NextCure (NXTC.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.61 dollars, previous value of -0.58 dollars, expected value of -0.59 dollars.
No Data